Residency · New York, NY
Sponsored by Icahn School of Medicine at Mount Sinai
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lancet (London, England) · 2024 · 228 citations · Robert Vitti
Primary Open-Angle Glaucoma Preferred Practice Pattern®.
Ophthalmology · 2021 · 379 citations · Kateki Vinod
Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective.
Progress in retinal and eye research · 2021 · 368 citations · Louis Pasquale
Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study.
Ophthalmology · 2024 · 71 citations · Joseph Panarelli
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Lancet (London, England) · 2024 · 110 citations · Robert Vitti
Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries.
Nature communications · 2021 · 354 citations · Louis Pasquale
Assessment of a Large Language Model's Responses to Questions and Cases About Glaucoma and Retina Management.
JAMA ophthalmology · 2024 · 110 citations · Kyle Hirabayashi, Laura Barna, Louis Pasquale
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.
Ophthalmology · 2026 · 26 citations · Robert Vitti